The hepatitis B virus (HBV) X protein (HBx) has a key role in the molecular pathogenesis of HBV-related hepatocellular carcinoma (HCC). However, the mechanism of HBx-mediated hepatocarcinogenesis remains to be elucidated. In this study, we aimed to better understand the effects of HBx on gene-expression profiles that participate in hepatocarcinogenesis and the mechanism by which HBx regulates these genes. Differentially expressed genes between L02-HBx and L02-Vector control cells were identified by microarray and validated using quantitative real-time PCR. HBx upregulates 456 genes and downregulates 843 genes, including programmed cell death 4 (PDCD4). PDCD4 was downregulated in clinical HCC specimens and the downregulation of PDCD4 in HCC is correlated with HBx. Furthermore, overexpression experiments in HCC cells proved that PDCD4 has strong tumor-suppressive effects both in vitro and in vivo, and may induce cell apoptosis to suppress the development of HCC. HBx induces expression of DNA methyltransferases (DNMTs), but failed to change the methylation status of the PDCD4 promoter. HBx downregulates PDCD4 expression at least partially through miR-21. Taken together, this study reported for the first time that HBx downregulates PDCD4 and upregulates miR-21 expression. The overexpression of PDCD4 could suppress tumorigenicity. The deregulation of PDCD4 by HBx through miR-21 represents a potential novel mechanism of the downregulation of PDCD4 in HBV-related HCC and provides new insights into HCC development.
INTRODUCTION
Hepatocellular carcinoma (HCC) is a common and aggressive cancer that is strongly associated with chronic infection by the hepatitis B virus (HBV). 1 The HBV X protein (HBx), an essential factor for HBV replication, is thought to have a key role in the molecular pathogenesis of HBV-related HCC. 2 HBx is widely believed to function as a transcriptional co-activator that exerts pleiotropic effects on diverse cellular functions. Previous studies revealed that HBx knocked into p21 locus caused HCC in mice. 3 However, the mechanism of HBx-mediated hepatocarcinogenesis is not well understood and remains to be elucidated.
The activation of proto-oncogenes and inactivation of tumorsuppressor genes (TSGs) have a critical role in inducing tumors. 4 In human HCC, a series of TSGs (including p53, M6P/IGF2R, p16INK4A, E-cadherin and RB) are mutated or downregulated when compared with noncancerous liver tissues. 5, 6 Furthermore, restoration of some of these genes is reported to reduce the malignant phenotype, 7 indicating that the TSGs have important roles in HCC development. PDCD4, a novel TSG, which is expressed ubiquitously in normal tissues with highest levels in liver was recently reported to be downregulated in HCC. 8 However, the mechanism of PDCD4 downregulation in HBV-related HCC remains to be defined.
In virus-associated cancers, viral proteins such as simian virus 40T antigen and the latent membrane protein 1 of Epstein-Barr virus have been shown to disturb the host DNA methylation system by upregulating DNA methyltransferases (DNMTs). Upregulation of DNMTs thereby inactivates TSGs and increases tumor susceptibility. 9, 10 Thus, in addition to having direct tumorigenic functions, viral proteins appear to participate in epigenetic alterations. In HCC, human hepatitis B virus (HBV) infection has been linked to chronic hepatitis, cirrhosis, and the development of HCC. 11 Studies have previously demonstrated that the most potent carcinogenic protein in HBV, the HBx protein, represses E-cadherin expression by promoter hypermethylation through activating the expression of DNMT1. 12 Park et al. 13 indicated that HBx can increase total DNMT activity by upregulating DNMT1, DNMT3A1 and DNMT3A2. In addition, evidence suggest that HBx can deregulate a set of microRNAs (miRNAs).
14 Thus far, large-scale miRNA-expression profiling of human cancers have revealed that miRNA deregulation is frequently associated with many solid and liquid tumors, including human HCC. 15, 16 These findings highlight the role of miRNA in cellular processes.
To gain a better understanding of the effects of HBx on transcriptional regulation and hepatocarcinogenesis, we examined the gene-expression profiles in immortalized human liver L02 cells stably transfected with HBx. We found that HBx represses PDCD4 expression. The downregulation of PDCD4 by HBx is not dependent on DNA methylation, and could be abolished by the knockdown of miR-21. Taken together, our data support the hypothesis that HBx repressed PDCD4 expression via the induction of miR-21 in HCC. In addition, we demonstrated a correlation between the expression of HBx and PDCD4/miR-21 in HCC patients, highlighting the clinical relevance of our observations. Furthermore, the overexpression of PDCD4 in HCC cell lines induced apoptosis and suppressed cell tumorigenicity abilities in vitro and in vivo.
RESULTS

HBx represses PDCD4 expression
We first examined the differential expression profiles in L02-HBx and control L02-Vector cells by complementary DNA (cDNA) microarray analysis. Results showed that expression levels of 1299 genes were remarkably altered. Of these altered genes, 456 genes were upregulated, and 843 genes were downregulated in L02-HBx cells (fold-change cutoff: 2.0, P-value cutoff: 0.05) (Figure 1a ). Gene ontology (GO)-assisted analysis of downregulated genes found that the molecular functions of these genes were mainly binding functions, including protein binding, DNA binding and nucleotide binding (Figure 1b) . In the biological processes category, the top ten significant GO groups to which the HBxdownregulated genes belong are cellular processes, cell cycle, metabolic processes, protein modification and other processes ( Figure 1c ). These processes were previously reported to be involved mainly in various pathological injuries to the liver or the development of HCC. 17, 18 PDCD4, a typical downregulated gene in L02-HBx cells, was selected for further research due to its involvement in eight of the top ten significant GO groups in biological processes. To further validate the candidate genes in cDNA microarray, we first detected HBx expression levels in 10 liver cell lines. The results showed that HBx was positive in 97H, 97L and HepG2.2.15 cells that constitutively replicate HBV (Supplementary Figure S1A) . The QSG-7701 and SMMC-7721 cells were transiently transfected with the pCDNA4-HBx and pCDNA4 vectors (Figure 2a) . Results showed that PDCD4 was downregulated in HBx-transfected cells compared with the control cells (vector) both at RNA and protein levels (Po0.05; Figures 2b and c) . Furthermore, the downregulation of PDCD4 by HBx is dose-dependent (Figure 2d ).
To further verify whether this downregulation correlated with HBx expression, we examined the expression of PDCD4 after HBx knockdown by RNAi. The results showed that HBx knockdown increased PDCD4 expression both at RNA and protein levels in L02-HBx no. 8 and 97H cells (Po0.05; Figures 2e and f) . These data supported the hypothesis that HBx downregulates PDCD4 expression.
The inhibition of PDCD4 expression by HBx does not occur at transcription level It has been suggested that hypermethylation of PDCD4 promoter is associated with its downexpression in gliomas. 19 We previously reported that knockdown of DNMT1 induced PDCD4 expression in SMMC-7721 cells. 20 Next, we aimed to investigate whether HBx regulates DNMTs' expression and inactivates PDCD4 via promoter hypermethylation. DNMTs expression analysis in QSG-7701 and SMMC-7721 cells showed that DNMT1 and DNMT3B were all upregulated to different degrees at RNA and protein levels in HBx-transfected cells (Figures 3a and b) .
Next, we investigated whether HBx induces hypermethylation of PDCD4 promoter by methylation-specific PCR. The results showed that HBx failed to hypermethylate PDCD4 promoter in QSG-7701 and L02 cells (Figure 3c, S1D) . Consistently, DNA methylation inhibitor 5 0 -Aza treatment did not change the expression of PDCD4 (Supplementary Figure S1C) . Furthermore, The bar plot shows the top ten enrichment score values of the significant enrichment terms of the biological processes. Count, the number of differentially expressed genes associated with the listed GOID. Enrichment Score, the GOID's Enrichment Score value, it equals ( À log 10 (P-value)).
we made luciferase assay using two functional PDCD4 promoterluciferase reporter constructs pGL3Fragdel1 and pGL3Frag3 (contain À 2253/ À 1999 and À 345/ À 50 of the basal promoter, respectively), and did not find any effects of HBx on PDCD4 at the transcription level (Figure 3d ). These results suggest that HBxdownregulated PDCD4 at later stages of gene expression, but not at the transcription level. miR-21 regulates PDCD4 expression in HCC Several studies previously demonstrated that PDCD4 3 0 -untranslated region is partially complementary to miR-21, 21, 22 and is a direct target gene of miR-21 in several cancer types. We confirmed the regulation of PDCD4 by miR-21 in the HCC cell line L02, 97H and HepG2.215. After transiently transfecting miR-21 inhibitor or negative control into these cells, we found that inhibition of miR-21 upregulated PDCD4 expression both at mRNA and protein levels (Po0.05; Figures 4a and b) . In clinical HCC tissues, qRT-PCR analysis of miR-21 expression (cohort 1, 19 cases) showed that miR-21 was overexpressed in 58% HCC tissues compared with the corresponding non-tumors ( Figure 4c ) and negatively correlated PDCD4 mRNA expression (Po0.01; Figure 4d ). When the HCC patients were divided into sub-groups based on their relative miR-21 status, the frequency of PDCD4 protein downregulation (ToN ) was higher in high miR-21 expression subgroups (Supplementary Figure S1E) . Furthermore, the expression of miR-21 was negatively correlated PDCD4 protein expression in cell lines (Po0.05; Figure 4e ). These results suggest that PDCD4 is negatively associated with miR-21 expression supporting the hypothesis that PDCD4 is regulated by miR-21 both at mRNA and protein level in HCC. miR-21 mediates the repression of PDCD4 by HBx It has been shown that HBx can deregulate the expression of cellular miRNAs. 14, 23, 24 Therefore, we examined whether HBx could deregulate a specific candidate miRNA (miR-21) and regulate PDCD4 expression. An HBx expression construct and HBx small interfering RNA (siRNA) were employed in HCC cell lines. In the present study, we found that overexpression of HBx increases miR-21 expression (Po0.05; Figure 5a ), while inhibiting HBx reduces miR-21 expression (Po0.05; Figure 5b ).
In clinical HCC cases, HCC patients were divided into subgroups based on their relative HBx mRNA status. Interestingly, we found that miR-21 was overexpressed in tumor in the clinical cases where HBx was highly expressed in tumor than in non-tumor tissues (Po0.05; Figure 5c (*Po0.05; **Po0.01). There was no significant difference about PDCD4 protein expression in L02-Vec cells after miR-21 inhibitor treatment. It may due to the relative low background expression level of miR-21 in L02-Vec cells and miR-21 may be not the main regulatory pathway about PDCD4 in these cells. Taken together, our data demonstrate that HBx downregulates PDCD4 expression at least partially through miR-21.
Restoration of PDCD4 could suppress tumor growth PDCD4 expression was analyzed by quantitative real-time PCR (qPCR) (cohort 2, 33 cases) and western blot analysis (cohort 1, 19 cases). Five representative results are shown in Figure 6b . As shown in Figure 6a , the PDCD4 mRNA expression was decreased in HCC tumors. Compared with the paired corresponding non-tumor tissues, 53% of HCC cases showed a downregulation of PDCD4 at the protein level (Figure 6b ). Expression of PDCD4 was further examined by immunohistochemistry in 39 pairs of HCC samples. The results showed that the PDCD4 protein was localized in the cytoplasm. The protein levels were significantly reduced in HCC cells when compared with the adjacent noncancerous hepatocytes in all of the cases tested (Figure 6c) .
We further evaluated the relationship between HBx and PDCD4 mRNA levels in HCC samples. When the HCC patients were divided into sub-groups based on their relative HBx mRNA status, the PDCD4 expression was lower in HBx (high) cases compared with the HBx (low) cases in tumor tissues (Po0.05; Figure 6e ). Figure 6d describes 10 representative cases. Therefore, the negative correlation between the expression of PDCD4 and HBx in HCC patients suggests that the expression of HBx and PDCD4 is clinically relevant.
We next introduced PDCD4 into the HCC cell lines to investigate the function of PDCD4. Enforced expression of PDCD4 was detected in PDCD4 transfectants (97H-P2, 97H-P8 and 7402-P6, 7402-P8, respectively) compared with the control cells (97H-C1 and 7402-C6) (Figure 6f ). The tumor-suppressive effects of PDCD4 were assessed using cell growth assays, foci formation assays and tumor xenograft experiments. Increased expression of PDCD4 in 7402-P6 cells resulted in significantly decreased cell growth when compared with the 7402-C6 cells (**Po0.01; Figure 6g ). In addition, the foci formation was significantly decreased in 7402-P6 cells compared with 7402-C6 cells (**Po0.01; Figure 6h) .
To explore the tumor-suppressive effects of PDCD4 in vivo, five nude mice (one mouse died) were inoculated subcutaneously with either 7402-P6 or 7402-C6 cells. Solid tumors were visible in all of the four mice injected with 7402-C6 cells within 4 weeks. However, tumors were not observed in all of the four mice injected with 7402-P6 cells (left panel; Figure 6i ). The 7402-C6 cell-induced tumor volume was 156.5 ± 135.0 mm 3 (right panel; Figure 6i ). Collectively, these data indicate that PDCD4 has tumor-suppressive effects both in vitro and in vivo.
PDCD4 induces apoptosis of human HCC cell lines
The role of PDCD4 in cell apoptosis was examined to explore the mechanism of PDCD4 in the development of HCC. Cell apoptosis was analyzed both quantitatively and morphologically. Increased expression of PDCD4 in 97H and 7402 cells resulted in significantly increased cell apoptosis (Figures 7a and b) . The apoptosis rate, detected by a flow cytometry assay, was 4.33% in the 97H-C1 cells. However, the rates were 9.30 and 13.68% in the 97H-P2 and 97H-P8 cells, respectively (Figure 7a ). For BEL-7402 cells, the apoptosis rate was 24.00, 22.48 and 8.22% in 7402-P6, 7402-P8 and 7402-C6 cells, respectively (Figure 7a ). Hoechst 33342 staining showed nuclear alterations of apoptosis-condensed and fragmented nuclei with a brighter blue fluorescence. The percentage of apoptotic cells was 18.2 ± 1.62, 16.6 ± 1.48 and 2.9 ± 0.44% in 7402-P6, 7402-P8 and 7402-C6 cells, respectively (Po0.05, Figure 7b ).
To further examine the function of PDCD4 in promoting apoptosis, we next measured the expression of several apoptosis-related proteins. As shown in Figure 7c , the overexpression of PDCD4 significantly elevated the expression of cleaved caspase-3 and caspase-9 in the 7402-PDCD4 cells compared with the 7402-control cells. The change in cleaved caspase-8 is not obvious. These results support that PDCD4 may induces cell apoptosis. We also detected the effects of PDCD4 on cell migration via woundhealing assays, and did not find significant difference between 7402-PDCD4 and 7402-control cells (Supplementary Figure S2B) .
DISCUSSION
The PDCD4 gene was first isolated from a human glioma cell cDNA library as a tumor-related gene. 25, 26 Accumulating evidence indicates that PDCD4 is a novel TSG. Loss or reduction of PDCD4 expression was found in several types of human primary tumors such as lung cancer, colorectal cancer 27 and glioma. 19 Studies of PDCD4 in HCC showed that PDCD4 is involved in transforming growth factor-b1-induced apoptosis, 8 and can effectively suppress the metastatic potential of HCC cells.
28 PDCD4-deficient mice developed spontaneous lymphomas 29 and increased sensitivity to chemical carcinogenesis, 30 and PDCD4 transgenic mice showed significant resistance to tumor induction. 31 Recently, Zhang et al.
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indicated that PDCD4 enhances the chemosensitivity of ovarian cancer cells. Our data indicated that PDCD4 has strong tumorsuppressive effects both in vitro and in vivo, and may induce cell apoptosis to suppress the development of HCC. Taken together, these data and our results suggest that PDCD4 has potential value as a molecular target in cancer therapy. 33 Therefore, investigation of the regulatory mechanism of PDCD4 is of interest.
It was reported that the mechanisms of downregulation of several tumor suppressors (such as p16, p27, Rb and p53) include point mutations, loss of heterozygosity and/or transcriptional repression by altered DNA methylation. 5, 34 In the present study, there is decreased expression of PDCD4 in human HCC tissues compared with the corresponding non-tumor liver tissues. The locus of PDCD4 is assigned to 10q24, and deletion of this region was reported in some cases of HCC. 35 However, deletion of the PDCD4 locus is noted only in minor cases of HCC. Therefore, mechanism(s) other than loss of heterozygosity or a point mutation will likely be involved in the downregulation of PDCD4. The HBV infection is a major risk factor for developing HCC, which is involved in at least 80% of HCC cases. 36 HBx is a multifunctional oncoprotein and has many roles in the development of HCC. We are the first to report an inverse correlation between HBx and PDCD4 expression in HCC patients, and HBx can downregulate PDCD4 expression both at RNA and protein levels.
Evidence demonstrates that HBx represses some gene expression (such as E-cadherin, IGFBP3, IL-4R and MT1F) by promoter hypermethylation.
12,13,37 Gao et al. 19 reported that PDCD4 expression was silenced by the methylation of its 5 0 CpG island in gliomas. We hypothesize that HBx may induce hypermethylation of the PDCD4 promoter region, thus decreasing its expression. The results showed that HBx induced DNMT1 and DNMT3B expression, but did not hypermethylate PDCD4 promoter. Our findings imply that downregulation of PDCD4 by HBx may not occur through hypermethylation of its promoter. Furthermore, reporter assays reveal that HBx does not affect PDCD4 expression at the transcription level. Several studies have previously demonstrated that PDCD4 is a direct target gene of miR-21. HBx deregulation of miRNA expression patterns has been reported. 14, 23, 24 Thus, we present a hypothesis where miR-21 may contribute to the HBx-mediated downregulation of PDCD4. We are the first to report that HBx upregulates miR-21 level. Further examination found that miR-21 was highly expressed in HCC tissues compared with the corresponding non-tumor liver tissues. Moreover, its expression was positively correlated with the HBx status. Taken together, our data demonstrate the clinical relevance of the observed HBxmediated upregulation of miR-21 in the cell lines studied. Importantly, we found that a miR-21 inhibitor was able to abolish the HBx-mediated downregulation of PDCD4 in L02-HBx cells. This finding suggests that HBx downregulates PDCD4 expression in hepatoma cells by enhancing the expression of miR-21. PDCD4 was also shown to be a direct target of miR-183. 38 However, whether other miRNAs are also involved in the regulation of PDCD4 remains unclear. Upregulation of miR-21 mediated by HBx might be one of mechanisms suppressing PDCD4 expression in HCC. The miR-21 inhibition in HepG2.215 cells did not induce high expression of PDCD4 mRNA, may explain that the HBx RNAi had no influence on PDCD4 mRNA expression in the same cell line, and support that HBx represses PDCD4 expression by miR-21. Our results by using a miR-21 inhibitor showed that miR-21 regulates PDCD4 both at the mRNA and protein expression levels. Previous studies implied that PDCD4 is also regulated at the protein level via the ubiquitin-mediated degradation through the phosphorylation of PDCD4 by PI3KmTOR/p70 S6K pathway. 30, 39 However, PTEN, a target of miR-21, which suppresses the PI3K/mTOR/S6K pathway, is also reported. Thus, other than direct binding, HBx-induced miR-21 may repress PDCD4 by S6K-mediated proteasome degradation. HBx has previously been shown to activate tumorpromoting signals including protein kinase C (PKC) and activator protein-1 (AP-1), 40, 41 and miR-21 is positively regulated by AP-1.
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The upregulation of miR-21 by HBx may be through AP-1. Moreover, AP-1 activity is reported to be negatively regulated by PDCD4, 43 leading to the formation of positive feedback loop between AP-1-miR-21-PDCD4. In addition, HBx-miR-21 may also repress PDCD4 expression by protein kinase C-mediated PI3K/ mTOR/S6K pathway.
In summary, we are the first to report that the downregulation of PDCD4 in HCC is correlated with HBx. The downregulation mechanisms of PDCD4 by HBx are at least partly through miR-21. Notably, the correlation between the expression of HBx and PDCD4 or miR-21 was observed in HCC patients, highlighting the clinical relevance of our observations. Thus, our findings offer a new regulatory mechanism of PDCD4 expression in HCC, enhancing the understanding of both the pleiotropic nature of the HBx viral protein and its contribution to HCC. Gene expression profiles and data analysis L02 cells were stably transfected with HBx-expressing constructs or control vectors in three biological replicates. Two HBx transfectants, L02-HBx no. 1 and L02-HBx no. 8, an L02-HBx mix and three L02-Vector control cell line cells were used to analyze the gene expression profiles by cDNA microarray. Differentially expressed mRNAs with statistical significance were identified through volcano plot filtering (fold-change filtering). GO analyses were applied to determine the roles that differentially expressed mRNAs had in these GO terms. Hierarchical clustering was performed to show distinguishable mRNA expression patterns among the samples.
MATERIALS AND METHODS
HCC patient samples
Reverse transcription reaction and qPCR
For the detection of miR-21 expression, stem-loop RT-PCR was performed as previously described. 44, 45 U6 small RNAs were used as an internal control. 38 The qPCR was carried out using the SYBR Premix Ex Taq (Takara, Dalian, China) according to the manufacturer's protocol. The relative expression was evaluated by the comparative CT method. The primer sequences of each gene and PCR conditions are shown in Supplementary  Table 2 .
Western blot analysis 
Immunohistochemical analysis
Paraffin sections (5 mm) were stained with the anti-PDCD4 antibody by incubating the samples overnight at 4 1C. Secondary staining with biotinconjugated anti-rabbit IgG, and tertiary staining with HRP-conjugated streptavidin were performed using an ABC kit (PK6100, Vector, Burlingame, CA, USA). Specific staining was visualized by 3, 3 0 -diaminobenzidine staining. The slides were then counterstained with hematoxylin. Images were captured using Nikon ECLIPSE TE2000-S microscope system (Nikon, Melville, NY, USA). according to the manufacturer's protocol. The stably expressing PDCD4 cells (97H-P2, 97H-P8, 7402-P6 and 7402-P8) and the control cells (97H-C1 and 7402-C6) were established, and cultured in medium with G418. For siRNA transfections, cells were transfected with 50 nmol/l HBx siRNA, a negative control, miR-21 inhibitor or an inhibitor-negative control using the X-tremeGENE siRNA Transfection Reagent (Roche) according to the manufacturer's protocol. After 48 h, cells were harvested for analysis.
RNA interference siRNAs targeting the HBx mRNA were designed and synthesized by GenePharma (Shanghai, China). The miR-21 inhibitor (Anti-has-miR-21, Cat. no. MIN0000076, a modified antisense of miR-21 mature sequence) and the inhibitor-negative control (NC, Cat. no. MSY0002505) were purchased from Qiagen (Germantown, MD, USA).
Methyl-specific PCR Genomic DNA was extracted from the cells by the phenol-chloroform method, followed by bisulfite modification as described previously. 46 The bisulfite-treated genomic DNA from the 7701-Vector, 7701-HBx, L02-Vector, L02-HBx no. 1 and L02-HBx no. 8 cells was specifically amplified using methylated and unmethylated PDCD4 primers as reported previously. 19 Luciferase assay pFL3Fragdel1 and pGL3Frag3 (gifts from Dr Heike Allgayer, University of Heidelberg) are two plasmids containing different functional promoter regions of PDCD4. 47 Cells were placed on 12-well tissue culture plates 24 h prior to transfection. A total of 0.5 mg of pFL3Fragdel1 or pGL3Frag3, or pGL3 Basic and 50 ng of pRL-TK were transfected with 0.5 mg of pCDNA4/ TO-HBx or pCDNA4/TO plasmids into the cells using FuGENEHD transfection reagent (Roche) according to the manufacturer's protocol. Thirty-six hours after transfection, luciferase assays were performed with dual-luciferase reporter assay system and a TD-20/20 luminometer (Promega, Madison, WI, USA).
Flow cytometry analysis
Detection of early apoptotic cells was performed using the annexin V-PI apoptosis detection kit (Biouniquer, Hangzhou, China). Briefly, cells were harvested and washed twice with cold phosphate-buffered saline, incubated in the dark at room temperature (25 1C) with annexin V-FITC and propidium iodide for 10 min, and then analyzed by flow cytometry. The cells that were annexin V-FITC þ (with translocation of phosphatidylserine from the inner to the outer leaflet of the plasma membrane) and propidium iodide À (with intact cellular membranes) were considered early apoptotic cells.
Hoechst 33342 staining for apoptotic morphology
The 7402-C6, 7402-P6 and 7402-P8 cells were stained with Hoechst 33342 (Dojindo Laboratories, Kumamoto, Japan) according to the manufacturer's protocol. One thousand cells were observed in five randomly chosen areas for each sample, and the percentage of apoptotic cells was calculated. The cells with condensed or fragmented nuclei were considered to be apoptotic. Fluorescent images were captured using the Nikon ECLIPSE TE2000-S microscope system. 
Measurement of cell proliferation
Statistical analysis
The independent Student's t-test was used to compare the results, expressed as the mean±s.d. between any two preselected groups. To determine correlations between variables, Pearson's correlation coefficient was calculated. A P-value o0.05 was considered statistically significant. ABBREVIATIONS DNMTs, DNA methyltransferases; HBV, hepatitis B virus; HBx, hepatitis B virus X protein; HCC, hepatocellular carcinoma; miRNA, microRNA; MSP, methylation-specific PCR; PDCD4, programmed cell death 4; qPCR, quantitative real-time PCR; siRNA, small interfering RNA; TSG, tumor-suppressor gene
